Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 9865963, 8 pages
https://doi.org/10.1155/2017/9865963
Review Article

A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease

1State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, China
2Department of Intensive Care Unit, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi 710068, China

Correspondence should be addressed to Yongquan Shi; nc.ude.ummf@nauqyihs

Received 21 April 2017; Accepted 25 July 2017; Published 22 August 2017

Academic Editor: Yusuke Sato

Copyright © 2017 Hongying Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. B. El-Serag, S. Sweet, C. C. Winchester, and J. Dent, “Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review,” Gut, vol. 63, no. 6, pp. 871–880, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Vakil, S. V. van Zanten, P. Kahrilas, J. Dent, and R. Jones, “The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus,” The American Journal of Gastroenterology, vol. 101, no. 8, pp. 1900–1920, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Vakil, “Disease definition, clinical manifestations, epidemiology and natural history of GERD,” Best Practice & Research. Clinical Gastroenterology, vol. 24, no. 6, pp. 759–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. F. K. Friedenberg, A. Hanlon, V. Vanar et al., “Trends in gastroesophageal reflux disease as measured by the National Ambulatory Medical Care Survey,” Digestive Diseases and Sciences, vol. 55, no. 7, pp. 1911–1917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Mody, D. Eisenberg, L. Hou, S. Kamat, J. Singer, and L. B. Gerson, “Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy,” ClinicoEconomics and Outcomes Research, vol. 5, pp. 161–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. L. B. Cross and L. N. Justice, “Combination drug therapy for gastroesophageal reflux disease,” The Annals of Pharmacotherapy, vol. 36, no. 5, pp. 912–916, 2002. View at Publisher · View at Google Scholar
  7. P. O. Katz, J. M. Scheiman, and A. N. Barkun, “Review article: acid-related disease—what are the unmet clinical needs?” Alimentary Pharmacology & Therapeutics, vol. 23, Supplement 2, pp. 9–22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Savarino, F. Di Mario, and C. Scarpignato, “Proton pump inhibitors in GORD: an overview of their pharmacology, efficacy and safety,” Pharmacological Research, vol. 59, no. 3, pp. 135–153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Fass, M. Shapiro, R. Dekel, and J. Sewell, “Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease—where next?” Alimentary Pharmacology & Therapeutics, vol. 22, no. 2, pp. 79–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. L. Peghini, P. O. Katz, N. A. Bracy, and D. O. Castell, “Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors,” The American Journal of Gastroenterology, vol. 93, no. 5, pp. 763–767, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. L. R. Lundell, J. Dent, J. R. Bennett et al., “Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification,” Gut, vol. 45, no. 2, pp. 172–180, 1999. View at Google Scholar
  12. D. J. Hetzel, J. Dent, W. D. Reed et al., “Healing and relapse of severe peptic esophagitis after treatment with omeprazole,” Gastroenterology, vol. 95, no. 4, pp. 903–912, 1988. View at Google Scholar
  13. W. Y. Chen, W. L. Chang, Y. C. Tsai, H. C. Cheng, C. C. Lu, and B. S. Sheu, “Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B,” The American Journal of Gastroenterology, vol. 105, no. 5, pp. 1046–1052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. C. Delchier, G. Cohen, and T. J. Humphries, “Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease,” Scandinavian Journal of Gastroenterology, vol. 35, no. 12, pp. 1245–1250, 2000. View at Google Scholar
  15. Y. Kinoshita and M. Hongo, “Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study,” The American Journal of Gastroenterology, vol. 107, no. 4, pp. 522–530, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Fass, S. J. Sontag, B. Traxler, and M. Sostek, “Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial,” Clinical Gastroenterology and Hepatology, vol. 4, no. 1, pp. 50–56, 2006. View at Google Scholar
  17. R. C. Orlando, S. Liu, and M. Illueca, “Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease,” Clinical and Experimental Gastroenterology, vol. 3, pp. 117–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. K. V. Vasiliadis, N. Viazis, J. Vlachogiannakos et al., “Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system,” The American Journal of Gastroenterology, vol. 105, no. 2, pp. 308–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. Galmiche, F. Zerbib, P. Ducrotte et al., “Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole,” Alimentary Pharmacology & Therapeutics, vol. 15, no. 9, pp. 1343–1350, 2001. View at Google Scholar
  20. R. Fass, “Healing erosive esophagitis with a proton pump inhibitor: the more the merrier?” The American Journal of Gastroenterology, vol. 107, no. 4, pp. 531–533, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. K. R. DeVault, “Overview of medical therapy for gastroesophageal reflux disease,” Gastroenterology Clinics of North America, vol. 28, no. 4, pp. 831–845, 1999. View at Google Scholar
  22. W. M. Simmonds, “Nonerosive reflux disease as a presentation of gastro-oesophageal reflux disease,” Official Journal of the South African Academy, vol. 4, no. 53, pp. 326–331, 2011. View at Google Scholar
  23. M. Gross, U. Beckenbauer, J. Burkowitz, H. Walther, and B. Brueggenjuergen, “Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany,” European Journal of Medical Research, vol. 15, no. 3, pp. 124–130, 2010. View at Google Scholar
  24. S. Toghanian, D. A. Johnson, N. O. Stalhammar, and F. Zerbib, “Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 National Health and Wellness Survey,” Clinical Drug Investigation, vol. 31, no. 10, pp. 703–715, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. P. O. Katz, L. B. Gerson, and M. F. Vela, “Guidelines for the diagnosis and management of gastroesophageal reflux disease,” The American Journal of Gastroenterology, vol. 108, no. 3, pp. 308–328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Fujiwara, Y. Habu, K. Ashida, M. Kusano, K. Higuchi, and T. Arakawa, “Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment,” Digestion, vol. 88, no. 3, pp. 145–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Fass, U. Murthy, C. W. Hayden et al., “Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 12, pp. 1595–1603, 2000. View at Google Scholar
  28. S. J. Spechler, P. N. Barker, and D. G. Silberg, “Clinical trial: intragastric acid control in patients who have Barrett’s oesophagus—comparison of once- and twice-daily regimens of esomeprazole and lansoprazole,” Alimentary Pharmacology & Therapeutics, vol. 30, no. 2, pp. 138–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Shimatani, M. Inoue, T. Kuroiwa, and Y. Horikawa, “Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression,” Alimentary Pharmacology & Therapeutics, vol. 19, no. 1, pp. 113–122, 2004. View at Google Scholar
  30. I. M. Gralnek, G. S. Dulai, M. B. Fennerty, and B. M. Spiegel, “Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials,” Clinical Gastroenterology and Hepatology, vol. 4, no. 12, pp. 1452–1458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Thornton and P. Lee, “Publication bias in meta-analysis: its causes and consequences,” Journal of Clinical Epidemiology, vol. 53, no. 2, pp. 207–216, 2000. View at Google Scholar